ABBOVE
8.9.2022 11:41:35 CEST | Business Wire | Press release
The Belgian solution provider Abbove, an emerging leader in the digital transformation of the wealth management industry, announces its partnership with Quintet Group’s Belgian branch Puilaetco to provide digital wealth planning services to their private banking clients. With the opportunity of expanding services to up to six new European countries, including the Netherlands, Denmark, Germany, and the United Kingdom, this marks another step for the company in spreading its wealth planning platform, if the Belgian pilot roll-out proves successful.
Currently, over 25,000 families in Europe received access to Abbove's platform via their trusted advisor. Starting today, Puilaetco's clients, who will use the technology under the name of “Richer Life Plan”, will expand that user base. By integrating the solution into their offer, the bank's advisors can now give their clients a global overview of their family's entire assets, as well as create simulations on the evolution of their wealth and the organization of their inheritance, all of this on a digital and 24/7 accessible platform.
“Since the beginning, it has been clear that our solution and vision are fully in tune with Quintet’s ambition. At Abbove, we develop a technology that helps financial institutions throughout the entire cycle of offering holistic wealth management services: from fully understanding a client’s global situation to delivering the best solutions based on his personal needs and guaranteeing a digital and interactive client experience. Not only our solution as such, but also our ambition to make our platform available internationally found a match with Quintet who have the will to spread the solution across their network in Europe after this first deployment in Belgium”, stated Guillaume Desclée, CEO and co-founder of Abbove.
Also commenting on the new partnership is Ludivine Pilate, Country CEO of Puilaetco: "With Richer Life Plan, we are entering a new era of customized wealth advice thanks to a complete and innovative technological solution. The tool perfectly matches our desire to strengthen the relationship of trust between our clients and our bankers: they share the same level of information, an indispensable basis for our experts to offer personalized solutions in terms of wealth structuring, investment, credit, or art advice.”
After opening up to banks across Europe at the beginning of June, this is the second private banking partnership announced by Abbove in three month’s time. The wealthtech’s solution is designed to help international banking groups add a digital and global layer to their wealth services so they can improve productivity, advice quality and user experience.
_____________________
About Abbove: Abbove SA is a Belgian WealthTech that develops a collaborative wealth planning platform for financial advisors and the families they accompany. Abbove’s technology helps financial advisors to digitize their wealth management services by improving the fluidity of internal processes and the client experience of the families they serve. The platform is currently distributed by 900 advisors to over 25,000 families in Europe. Visit www.abbove.com for more information.
About Puilaetco: With nearly 200 highly qualified employees and around ten billion euros of assets under management, Puilaetco, a Quintet Private Bank (Europe) S.A. Branch is a Belgian asset manager (founded in 1868) that offers its clients a personalized approach that is both innovative and traditional. As a trusted partner, the bank has been offering efficient, personalized and responsible solutions for five generations. These services include asset management, financial and estate planning, loans and artistic asset management.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005531/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
